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Abstract:
Objective: Venous, arterial, and microcirculatory events are frequently encountered in the clinical course of essential 
thrombocytosis and polycythemia vera. We aimed to investigate the levels of soluble endothelial protein C receptor (sEPCR) 
in myeloproliferative diseases to see whether there was a difference between the patients with and without history of 
thromboembolism. 
Materials and Methods: The study included patients with polycythemia vera (n=12), patients with essential thrombocytosis 
(n=13), and controls (n=29). In all groups, we measured proteins C and S, antithrombin and sEPCR levels, and plasma 
concentrations of thrombin-antithrombin complex, prothrombin fragments 1+2, and D-dimer. 
Results: Comparing the patients with and without history of thromboembolic attack, statistically significant differences were 
not observed in terms of sEPCR, D-dimer, thrombin-antithrombin complex, prothrombin fragments 1+2, and hematocrit levels 
(p=0.318, 0.722, 0.743, 0.324, and 0.065, respectively). 
Conclusion: Significant increase in the parameters that reflect activation of coagulation, such as sEPCR, thrombin-
antithrombin complex, prothrombin fragments 1+2, and D-dimer, reflects the presence of a basal condition that leads to a 
tendency toward thrombosis development in ET and PV when compared to healthy controls.
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Özet:
Amaç:  Esansiyel trombositemi (ET) ve polisitemi vera (PV)’nin klinik seyrinde venöz, arteriyel ve mikrosirkülatuar trombotik 
olaylara sık olarak rastlanmaktadır. Biz, tromboembolik olay öyküsü olan ve olmayan hastalardaki çözünür endotelyal protein 
C reseptörü (sEPCR) düzeyleri açısından bir fark olup olmadığını araştırmayı amaçladık.
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Gereç ve Yöntemler: Çalışmaya polisitemia vera (12) ve esansiyel trombositozu (13) toplam 25 hasta ile kontrol grubunu 
oluşturmak üzere 29 sağlıklı kişi alındı. Her iki grupta da, protein C, S, antitrombin ve sEPCR ile düzeyleri ile trombin-
antitrombin kompleks (TAT), protrombin fragmanı 1+2 ve D-Dimer plazma konsantrasyonları ölçülmüştür.
Bulgular: Tromboembolik atak öyküsü olan ve olmayan hastalar karşılaştırıldığında sEPCR, D-dimer, TAT, protrombin 
fragman 1 +2 (F1+2) ve hematokrit düzeyleri açısından istatistiksel olarak anlamlı fark gözlenmemiştir (sırasıyla p=0,318; 
0,722; 0,743; 0,324; 0,065).
Sonuç: sEPCR, TAT, F1+2 ve D-Dimer gibi pıhtılaşma aktivasyonunu yansıtan parametrelerinde anlamlı artış görülmesi, 
parametrelerde literatür ile uyumlu olarark kontrol grubuna göre anlamlı artış gösterilmiş olması ET ve PV hastalarında 
tromboza eğilim oluşturan bazal bir durumun varlığına işaret etmektedir.
Anahtar Sözcükler: Miyeloproliferatif hastalıklar, Endotelyal protein C reseptörü, Tromboz
Introduction
Protein C is a vitamin K-dependent anticoagulant 
synthesized largely in the liver that plays an important role 
in the coagulation system [1]. Activation of protein C is 
catalyzed by the thrombin-antithrombin (TAT) complex 
[2]. Activated protein C (aPC), combined with its cofactor, 
protein S, acts as an anticoagulant, inactivating factor Va 
and factor VIIIa [3]. In recent years studies have shown 
that, in addition to its important role in the coagulation 
system, protein C also has cell protection functions such 
as maintenance of the vascular barrier (continuity of its 
integrity), inhibition of apoptosis, and inflammation 
control [2,4]. The endothelial protein C receptor (EPCR), 
which is a type of transmembrane glycoprotein found 
in the endothelium that was first defined by Fukudome 
and Esmon in 1994, also enables activation of protein 
C [5]. EPCR augments the activation of protein C by 
approximately 10 times by binding to protein C on the 
cell surface [4,6]. The activation of protein C is increased 
by binding to the EPCR via the TAT complex [7]. EPCR 
is found on the surface of all vessels, particularly large 
vessels. Thrombin and inflammatory cytokines induce 
metalloprotease activity on the cell surface and lead to 
the production of soluble EPCR (sEPCR). Soluble EPCR 
is the ligand-binding type of EPCR and can be detected 
in plasma [4]. Anti-sEPCR has recently been discovered 
in human plasma [3]. sEPCR inhibits the anticoagulant 
effect of aPC by inhibiting the attachment of the protein 
to phospholipids and inactivating factor Va. This tends to 
lead to the development of thrombosis [1].
Essential thrombocytosis (ET) and polycythemia vera 
(PV) are chronic myeloproliferative diseases (CMPDs). 
These are clonal hematopoietic stem-cell diseases 
characterized by an increase in leukocyte, erythrocyte, and 
platelet production [8]. Venous and arterial thrombosis and 
microcirculatory events are frequently encountered in the 
clinical course of ET and PV.
The tendency to develop thrombosis is enhanced in these 
diseases due to hyperviscosity, qualitative and quantitative 
abnormalities in blood cells, increased production of 
thromboxane A2, leukocyte activation, and endothelial 
damage [9]. Hereditary and acquired thrombophilic 
states (factor V Leiden mutation analysis, homocysteine 
levels, presence of antiphospholipid antibodies) have been 
investigated in patients with CMPDs [10].
In this study, we aimed to investigated the sEPCR levels 
in CMPDs and to determine potential differences between 
patients with and without a history of thromboembolism. 
Only one study to date appears to have investigated the role 
of levels of natural anticoagulants (protein C, protein S, and 
antithrombin) in the etiology of thromboembolism in CMPDs; 
this study detected low levels in patients who had experienced 
a thrombotic attack [9]. In our study, we to investigated the 
association of protein C, protein S, antithrombin levels, plasma 
concentrations of the TAT complex, prothrombin fragments 
1+2 (F1+2), D-dimer and sEPCR levels with development of 
thrombosis in ET and PV patients.
Materials and Methods
Study Group
The study included patients with PV (n=12) and ET 
(n=13) who were over 18 years of age, had been followed in 
the hematology clinic of Başkent University Medical Faculty 
for 5 years, and had agreed to participate in the study, as 
well as 29 healthy volunteers. Nine milliliters of venous 
blood was collected by venipuncture in tubes containing 
sodium citrate from all patients and controls. Plasma was 
obtained by centrifugation at 2300 x g for 10 min at room 
temperature and immediately stored at -80 °C until use. 
Soluble EPCR levels were determined in plasma with sEPCR 
Asserachrom enzyme-linked immunosorbent assay (ELISA) 
kits (Asserachrom® sEPCR, Diagnostica Stago) according to 
the manufacturer’s instructions.
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Regular C-reactive protein (CRP) levels were studied 
simultaneously to exclude inflammation. The TAT complex, 
F1+2, and D-dimer, were analyzed using an ELISA kit 
(Enzygnost F1+2, Enzygnost TAT, Dade Behring; D-dimer: 
Asserachrom, Roche Diagnostics). Levels of antithrombin 
and protein C, which are natural anticoagulants, were 
quantitatively measured by the colorimetric method 
(STA, Stachrom Analyzer); total protein S was measured 
quantitatively by the immunoturbidimetric method (STA, 
Stachrom Liatest). Informed consent was obtained from all 
patients and healthy volunteers. The study was started after 
obtaining the approval of the local ethics committee.
Statistical
SPSS 15.0 for Windows was used for statistical analysis. 
Categorical variables are represented in frequency tables, 
whereas numerical variables are represented as descriptive 
statistics [mean, standard deviation (SD), minimum, and 
maximum]. Cross-table statistics are given for the categorical 
comparison of the groups, and the chi-square test was 
used to identify the significance level. Analysis of variance 
was used for the comparison of more than 2 groups with 
normally distributed data, and the Kruskal-Wallis test was 
used for data not distributed normally. The level of statistical 
significance was considered to be a p-value of less than 0.05.
Results
The study included 25 patients with PV and ET and 29 
healthy controls. In the patient group, 48% (n=12) had PV 
and 52% (n=13) had ET. The mean age ± SD of the patients 
with PV and ET and of the members of the control group 
was 64.4±10.4, 68.4±12.1, and 49.5±10.7, respectively 
(p<0.001). The mean hematocrit level was statistically 
significantly higher in the control group, whereas the mean 
platelet, creatinine, CRP, D-dimer, TAT, F1+2, and sEPCR 
levels were statistically significantly higher in the patient 
group (Figures 1, 2, and 3). There was no correlation in 
the statistical comparisons of the protein C, protein S, and 
antithrombin levels between the patient and the control 
groups (p=0.821, p=0.984, and p=0.360, respectively). 
There was a positive correlation between protein C and 
S levels in patients with ET, whereas there was a negative 
correlation between protein S and antithrombin levels in the 
same group (Table 1). There was, however, no association 
between these levels in patients with PV.
A statistically significant difference was identified 
between the groups in hematocrit, platelet, creatinine, CRP, 
D-dimer, TAT, F1+2, and sEPCR levels and in hypertension 
(HT) and coronary arterial disease (CAD) rates. The mean 
hematocrit level was higher, whereas CRP and D-dimer 
levels were lower, in the control group compared to the ET 
group. The mean platelet, TAT, F1+2, and sEPCR levels were 
lower in the control group, but the mean creatinine level 
was higher compared to the ET and PV groups (Table 1). 
Levels of sEPCR in patients with PV were not correlated 
with TAT, D-dimer, or F1+2 levels (p=0.656, p=0.137, and 
p=0.095, respectively). The sEPCR levels in patients with ET 
were also not correlated with those of TAT, D-dimer, or F1+2 
(p=0.946, p=0.852, and p=0.691, respectively) (Table 1). 
In this study, 92% (n=23) of the patients had been 
receiving antiaggregant therapy and 12% (n=3) had been 
receiving anticoagulant therapy. Seventy-two percent of the 
patients had been receiving hydroxyurea. Phlebotomy was 
performed in 41.7% (n=5) of the patients with PV, whereas 
the remainder had been receiving either hydroxyurea or 
interferon therapy. Of the patients with ET, 46.2% (n=6) 
had been receiving anagrelide and 76.9% (n=10) had been 
receiving hydroxyurea. Among all patients, the prevalence 
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Figure 2. Mean TAT levels in PV, ET, and control groups and 
95% CI.
Figure 3. Mean prothrombin fragment 1+2 levels in PV, ET, 
and control groups and 95% CI.
Figure 1. Mean sEPCR levels in PV, ET, and control groups 
and 95% CI.
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of cerebrovascular incidents was 12% (n=3) and the 
prevalence of thromboembolic incidents was 44% (n=11). 
Arterial thromboses were detected in the majority of the 
patients (32%, n=8) who developed thrombosis. Most 
of these were cerebral (24%, n=6) or involved the lower 
extremities (8%, n=2), abdomen (8%, n=2), or coronary 
artery (4%, n=1). Four (16%) of the patients who had 
been receiving antiaggregant therapy developed a second 
attack, mostly in the form of a cranial thromboembolic 
event (Table 2). In terms of thromboembolic episodes and 
the number, location, and type of thromboses, there was 
no statistically significant difference between patients with 
ET and PV. Erythromelalgia was found in 2 of the patients 
with ET, and signs of hyperviscosity were observed in 5 
of the patients with ET. Hypermetabolic symptoms were 
present in 38.5% of the patients. There was no statistically 
significant difference between the patients with ET 
and PV in terms of the history of and the number of 
thromboembolic attacks, or in the type and localization of 
thrombosis (Table 2).
Comparing the patients with and without a history 
of thromboembolic attack, no statistically significant 
difference was observed in the sEPCR, D-dimer, TAT, F1+2, 
and hematocrit levels (p=0.318, p=0.722, p=0.743, p=0.324, 
and p=0.065, respectively). However, the difference in the 
leukocyte and platelet counts was statistically significant 
(p=0.010 and p=0.027, respectively) (Table 3).
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Table 1. Laboratory parameters in disease control groups.
 PV ET Control p
Female, (n,%) 7 (58.3) 10 (76.9) 12 (41.4)
0.096
Male, (n,%) 5 (41.7) 3 (23.1) 17 (58.6)
Age (years) 64.4±10.4 68.4±12.1 49.5±10.7 <0.001
Hematocrit, % 41.7±4.5 38.7±8.4$ 45.2±5.0# 0.020
White blood cells, /µL 9675.8±3827 7350.8±5357.9 6640.8±1662.8 0.053
Platelets, /µL 328333.3±138333$ 498000±322802$ 231069±42885# <0.001
AST, U/L 23.3±13.2 24.8±8.7 20.7±8.4 0.506
ALT, U/L 21.7±15.1 22.5±11.9 22±8.1 0.455
Creatinine, mg/dL 1.1±0.4$ 1±0.2$ 0.7±0.2*# 0.001
CRP, mg/L 3.2±2.4$ 3.7±2.6$ 1.7±2.1*# 0.008
D-dimer, ng/mL 0.2±0.2 0.3±0.2$ 0.2±0.2# 0.027
ProteinC, % 84.7±38.1 94.3±21.4 103±23.2 0.251
ProteinS, % 87.3±34.8 77.1±22.8 94.1±30.5 0.239
Antithrombin, % 106.3±19.8 110.3±19.5 106.3±22.2 0.285
TAT, ng/mL 199.0±103.7$ 218.5±104.3$ 2.5±5.1*# <0.001
Prothrombin fragment 1+2 level, nmol/L 1091.6±294$ 1285.9±145$ 543.4±246# <0.001
sEPCR, ng/mL 788.8±184#$ 1039.5±403$* 524.5±272*# <0.001
HT, (n,%) 8 (66.7) 11 (84.6) 0 (.0) <0.001
CAD, (n,%) 1 (8.3) 3 (23.1) 0 (.0) 0.025
Smoking , (n,%) 3 (25) 3 (23.1) 13 (44.8) 0.339
 
Data are presented as mean±standard deviation.
*Different from PV
#Different from ET
$Different from the control group 
(AT: antithrombin, CAD: coronary artery disease, CRP: C-reactiveprotein, ET: essential thrombocytosis, HT: hypertension, PV: polycytemia vera,  
sEPCR: soluble endothelial protein C receptor, TAT: thrombin-antithrombin complex) 
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Discussion
To the best of our knowledge, this is the first study to 
evaluate levels of sEPCR in ET and PV patients. The mean 
sEPCR was 524±272 ng/µL in the control group versus 
788.8±184 ng/µL in the ET group and 1039.5±403 ng/µL in 
the PV group. The sEPCR level was statistically significantly 
higher in the ET and PV patients compared to the control 
group (p<0.001). Elevated levels of sEPCR reflect a high 
possibility of a prothrombotic state. However, there was 
no statistically significant difference between the patients 
with and without thrombosis in terms of the sEPCR levels 
(p=0.318). In this study, levels of coagulation activation factors 
TAT, D-dimer, and F1+2 were also higher in the ET and PV 
patients compared to the control group (p<0.001, p=0.027, 
and p<0.001, respectively). These results confirmed enhanced 
coagulation activation. Unexpectedly, no correlation was seen 
between levels of sEPCR and these coagulation markers in the 
ET and PV patient groups. This situation may be attributed to 
the small number of patients in the trial.
In general, sEPCR has a procoagulant character. It is 
known that hereditary defects in the protein C system 
lead to an increase in the propensity to develop venous 
thromboembolism [11]. It has been reported that the 
attachment of A23 bp changes the function of EPCR, leading 
to sequential protein synthesis, which is not expressed on 
the epithelial surface. However, the role of this mutation 
in thrombosis is difficult to detect because of its low allele 
frequency [7,12]. An elevated level of sEPCR also impairs 
EPCR-mediated coagulation. Studies with healthy subjects 
demonstrated that the plasma sEPCR level shows a bimodal 
distribution with age [4,13]. Orhon et al. conducted a study 
with healthy children and adults and detected an increase in 
levels of the sEPCR in 20% of children and 10% of adults. 
The physiological basis of this bimodal distribution is 
unclear. Genetic factors such as sex and polymorphisms, as 
well as environmental factors such as smoking and dietary 
habits, have been considered responsible [13]. The Paris 
Thrombosis Study investigated genetic risk factors that 
facilitate venous thromboembolism and compared 338 
Table 2. Clinical features of patient groups.
PV ET p
Erythromelalgia, n (%) 0 (0) 2 (15.4) N/S
Hyperviscosity, n (%) 1 (8.3) 5 (38.5) N/S
TIA, n (%) 1 (8.3) 2 (15.4) N/S
Hemorrhage, n (%) 0 (0) 1 (7.7) N/S
Thromboembolic episodes n (%) 5 (41.7) 6 (46.2) N/S
Arterial thrombosis, n (%) 2.0 (16.7) 6.0 (46.2) N/S
Venous thrombosis, n (%) 3.0 (12) 0 (0) N/S
 
TIA: Transient ischemic attack, N/S: not specified
Table 3. Laboratory values of history with and without thromboembolic event in patients.
 
Thromboembolic event
 (+) (n=11)
Thromboembolic event 
(-)  (n=14)
p
sEPCR, ng/mL 841.6±337.1 980.1±336.1 0.318
D-dimer, ng/mL 0.3±0.2 0.3±0.2 0.722
TAT, ng/ml 226.3±113.7 195.7±94.5 0.743
Prothrombin fragment
1253.5±123.4 1144.8±306.1 0.324
F1+2 level, nmol/L
Hematocrit, % 37.3±7.2 42.4±5.9 0.065
White blood cells,  /µL 6131.8±3239 10301.4±5017.8 0.01
Platelets,  /µL 278636.4±129429 524928.6±290802.2 0.027
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patients with thrombosis (deep venous thrombosis and/or 
pulmonary embolus) and a control group comprising an 
equal number of subjects. The study found that carrying 
the A3 haplotype is associated with an increase in the level 
of sEPCR and an increase in the risk for thrombosis [14]. 
Another study found that the plasma sEPCR level was no 
lower than 100 ng/mL in pediatric stroke patients with the 
A3 haplotype, and that the sEPCR level was higher in a stroke 
group compared to a control group. Based on these results, 
the authors concluded that the sEPCR level is higher than 
normal in those with the A3 haplotype, and that this might 
be associated with a tendency to develop thrombosis [15]. In 
an analysis of plasma sEPCR levels in 82 patients with retinal 
venous occlusion, it was observed that the sEPCR level was 
statistically significantly higher in those with central venous 
occlusion compared to a control group. The same study failed 
to detect a statistically significant difference between the 
time to thrombosis development and the sEPCR level [16]. 
In another prospective study published recently, the authors 
concluded that the sEPCR level was high in CAD patients, but 
there was no significant difference in sEPCR levels between 
individuals with or without future cardiovascular event [17]. 
Essential thrombocytosis and PV are clonal hematopoietic 
stem cell-originated CMPDs associated with an increase in 
leukocyte, platelet, and erythrocyte production [18,19]. 
In these patients, thromboembolic complications are the 
second most frequent cause of mortality after hematological 
transformation [20]. In the present study, the prevalence of 
thromboembolic events was 41.7% in the ET patients and 
46.2% in the PV patients. These findings are consistent with 
the literature. Thromboembolic events were mostly cerebral 
in the PV patients, and lower extremity thrombosis was more 
common in the ET patients. Although arterial thrombosis 
was more prevalent in the PV patients, the prevalence of 
arterial thrombosis and venous thrombosis was the same 
in the ET patients. None of the patients had been receiving 
treatment at the time of their first thromboembolic event 
because they had no known myeloproliferative diseases. 
All 4 patients who had had a second thrombosis had been 
receiving treatment. Only 1 patient developed coronary 
arterial thrombosis during follow-up while receiving 
treatment. In the literature, the prevalence of thrombosis 
at the time of diagnosis was 11%-25% in ET patients and 
12%-39% in PV patients [21]. Two prospective studies 
(ECLAP and MRC-PT1) with large patient series reported 
an annual risk for cardiovascular events for each patient of 
2.5%-5% in PV patients and 1.9%-3% in ET patients [22,23]. 
Although major arterial events (acute myocardial infarction, 
ischemic stroke, peripheral arterial obstruction, etc.) are 
more prominent in PV patients, microcirculatory events 
(erythromelalgia, transient ischemic attack, visual and 
auditory defects, recurrent headaches, etc.) are encountered 
more frequently in ET patients. Venous events such as deep 
venous thrombosis of the lower extremities and pulmonary 
embolus are frequent in both patient groups [19]. In the 
ECLAP study, which included 1630 patients with PV, 39% 
of the patients had a history of thrombosis, and this was the 
most important cause of mortality (41%). Although an age 
of over 60 years and a history of previous thrombosis have 
been considered as the main factors that increase the risk for 
thrombosis, multivariable analyses have demonstrated that 
smoking, hypertension, and congestive heart failure might 
also be associated with an increased risk of thrombosis. The 
same study demonstrated no relation between the platelet 
count and thrombosis [22]. Another study demonstrated 
that acquired aPC resistance occurred in CMPD patients. 
Decreased levels of protein S and protein C are the probable 
cause of the prothrombotic state [9,24]. We detected no 
difference among the PV and ET patients and control group 
members in terms of levels of protein C, protein S, and 
antithrombin (p=0.251, p=0.239, p=0.285, respectively). 
This situation is attributed to the small number of patients 
in our study.
Leukocytosis was shown to be associated with 
thrombosis in patients with PV and ET [25]. The 
mechanism was considered to be an aggregation of platelets 
and neutrophils after leukocyte activation. On the contrary, 
in our study leukocyte and platelet counts were found to be 
significantly lower in patients with thromboembolic attack 
than in patients without it. This could be secondary to the 
use of hydroxyurea. Three metaanalyses were published. 
In these studies, JAK2V617F positivity is associated with 
increased thrombotic attacks [26,27,28]. At the time of our 
study, JAK2V617F mutation analysis was not used routinely 
in our laboratories. It was thus not applied to our patient 
group.
In conclusion, the lack of a statistically significant 
difference in the sEPCR levels of the ET and PV patients with 
and without thrombosis is attributed to the small number of 
patients in this trial. The significant increases in sEPCR, TAT, 
F1+2, and D-dimer levels reflect the activation of coagulation 
and point to the presence of a basal condition that leads 
to a tendency to develop thrombosis. Large-scale studies 
with more patients are needed to determine the predictive 
importance of high levels of sEPCR in the development of 
thrombotic events in patients with PV and ET.
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